GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EPIRUS Biopharmaceuticals Inc (OTCPK:EPRSQ) » Definitions » PB Ratio

EPIRUS Biopharmaceuticals (EPIRUS Biopharmaceuticals) PB Ratio : 0.00 (As of May. 29, 2024)


View and export this data going back to 2005. Start your Free Trial

What is EPIRUS Biopharmaceuticals PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-29), EPIRUS Biopharmaceuticals's share price is $1.0E-5. EPIRUS Biopharmaceuticals's Book Value per Share for the quarter that ended in Mar. 2016 was $1.00. Hence, EPIRUS Biopharmaceuticals's PB Ratio of today is 0.00.

The historical rank and industry rank for EPIRUS Biopharmaceuticals's PB Ratio or its related term are showing as below:

EPRSQ's PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2.53
* Ranked among companies with meaningful PB Ratio only.

Back to Basics: PB Ratio


EPIRUS Biopharmaceuticals PB Ratio Historical Data

The historical data trend for EPIRUS Biopharmaceuticals's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EPIRUS Biopharmaceuticals PB Ratio Chart

EPIRUS Biopharmaceuticals Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.73 2.66 - 2.26 2.07

EPIRUS Biopharmaceuticals Quarterly Data
Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.86 2.27 2.13 2.07 2.69

Competitive Comparison of EPIRUS Biopharmaceuticals's PB Ratio

For the Biotechnology subindustry, EPIRUS Biopharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EPIRUS Biopharmaceuticals's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EPIRUS Biopharmaceuticals's PB Ratio distribution charts can be found below:

* The bar in red indicates where EPIRUS Biopharmaceuticals's PB Ratio falls into.



EPIRUS Biopharmaceuticals PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

EPIRUS Biopharmaceuticals's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Mar. 2016)
=1.0E-5/0.999
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


EPIRUS Biopharmaceuticals  (OTCPK:EPRSQ) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


EPIRUS Biopharmaceuticals PB Ratio Related Terms

Thank you for viewing the detailed overview of EPIRUS Biopharmaceuticals's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


EPIRUS Biopharmaceuticals (EPIRUS Biopharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
699 Boylston Street, Eighth Floor, Boston, MA, USA, 02116
EPIRUS Biopharmaceuticals Inc is a global biopharmaceutical company focused on building biosimilar business targeting rare diseases by improving patient access through cost-effective medicines. The product candidates of the company are BOW080 for the potential treatment of ultra-rare blood disorders and BOW070 for the potential treatment of an uncommon lymphoproliferative disorder known as Castleman's disease. The group generally operates through the United States.
Executives
Vincent Aurentz officer: Chief Business Officer C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Thomas A. Shea officer: Chief Financial Officer C/O EPIRUS BIOPHARMACEUTICALS, INC., 699 BOYLSTON STREET 8TH FLOOR, BOSTON MA 02116
Amit Munshi director, officer: Chief Executive Officer C/O EPIRUS BIOPHARMACEUTICALS, INC., 699 BOYLSTON STREET, 8TH FLOOR, BOSTON MA 02116
Scott M Rocklage director, 10 percent owner C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Julie Mchugh director C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Mark Corrigan director
Geoffrey M Duyk director 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102
J Kevin Buchi director 41 MOORES ROAD, FRAZER PA 19355
Montreux Equity Partners Iv Lp 10 percent owner ONE FERRY BUILDING,, SUITE 255, SAN FRANCISCO CA 94111
5am Ventures Iii, L.p. 10 percent owner 2200 SAND HILL ROAD, SUITE 110, MENLO PARK CA 94025
5am Co-investors Iii, L.p. 10 percent owner 2200 SAND HILL ROAD, SUITE 110, MENLO PARK CA 94025
Andrew J. Schwab 10 percent owner C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
John D Diekman 10 percent owner C/O 5 AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Partners Iii, Llc 10 percent owner 2200 SAND HILL ROAD STE 110, MENLO PARK CA 94025
David Bonderman 10 percent owner 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102

EPIRUS Biopharmaceuticals (EPIRUS Biopharmaceuticals) Headlines

From GuruFocus

CEO of Epirus Biopharmaceuticals Buys 10,000 Shares

By Jennifer Chiou Jennifer Chiou 09-23-2015